Communiqués Oxford BioDynamics Plc

Actions

OBD

GB00BD5H8572

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:04 13/08/2026			Varia. 5j.	Varia. 1 janv.
0,1300 ^GBX	0,00%		+17,12%	-39,53%

20:57	RÉSULTATS ET ACTIVITÉ : tinyBuild poursuit Max Ent ; les pertes de Light Science se creusent	AN
12/08	PALMARÈS : 80 Mile chute après un retard au Groenland ; rachat d'actions pour Bravura	AN

Communiqués

22/12	Oxford BioDynamics : 22 Dec 2025 – Annual report and accounts for the year ended 30 September 2025	PU
16/12	Oxford BioDynamics : 16 Dec 2025 – Preliminary results for the year ended 30 September 2025	PU
09/07/25	Oxford BioDynamics : 30 June 2025 – Interim results for the six-month period ended 31 March 2025”	PU
01/07/25	Oxford BioDynamics : 30 June 2025 – Interim results for the six-month period ended 31 March 2025	PU
05/02/25	Oxford BioDynamics’ EpiSwitch® CRC Blood Test Accurately Detects both Cancer and Polyps	BU
25/07/24	Oxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA.	BU
25/06/24	Oxford BioDynamics part of consortium shortlisted for Strategic Government Initiative to Improve Cancer Immunotherapy	BU
04/06/24	Oxford BioDynamics Develops a High Accuracy, Discriminating Diagnostic Test for Multiple Canine Cancers	BU
19/10/23	Oxford BioDynamics Plc - Bupa UK to cover EpiSwitch CiRT for customers with cancer	AQ
18/10/23	Bupa UK to cover EpiSwitch® CiRT for customers with cancer	BU
04/10/23	Oxford BioDynamics receives reimbursement code for EpiSwitch Prostate Screening Test	AQ
03/10/23	Oxford BioDynamics Receives Reimbursement Code for EpiSwitch® Prostate Screening (PSE) Test	BU
27/09/23	Oxford Biodynamics launches the 94% accurate EpiSwitch Prostate Screening blood test for men with prostate cancer risk in the US and UK	AQ
26/09/23	Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk	BU
07/02/23	Oxford Biodynamics' Prostate Screening EpiSwitch blood test significantly enhances overall detection accuracy for at risk men	AQ
06/02/23	Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men	BU
19/12/22	Massachusetts General Hospital reports results of Interim Analysis from REFINE-ALS biomarker trial by Mitsubishi Tanabe Pharma USA, utilizing Oxford Biodynamics' EpiSwitch platform for prognostic stratification of fast progression ALS	AQ
19/12/22	Oxford BioDynamics in San Francisco for the 41st Annual J.P. Morgan Healthcare Conference	BU
16/12/22	Massachusetts General Hospital Reports Results of Interim Analysis from REFINE-ALS Biomarker Trial by Mitsubishi Tanabe Pharma USA, Utilizing Oxford Biodynamics’ EpiSwitch® Platform for Prognostic Stratification of Fast Progression ALS	BU
22/11/22	Prominent oncologist to discuss advantages of Oxford BioDynamics	AQ
21/06/22	Oxford BioDynamics’s Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK	BU
25/02/22	Oxford BioDynamics Announces US Launch of Its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for Oncology	BU
31/08/21	Oxford BioDynamics : Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer Therapies	BU
18/05/21	Oxford BioDynamics : The Prime Meridian Group Collaborates With Oxford BioDynamics Plc On Market Research	PR
02/11/20	Oxford BioDynamics : Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitch™ Disease Severity Program for COVID-19	BU